tbuckley/cabot-search huggingface dataset:
Low-dose chemotherapy with methotrexate and vinblastine for patients with refractory desmoid tumors: A second report of relationship between efficacy and various factors.
Authors: Yoshihiro Nishida, Tomohisa Sakai, Koki Shimizu, Hiroshi Urakawa, Eisuke Arai, Kunihiro Ikuta, Yuichi Ando, Naoki Ishiguro
Journal: Journal of Clinical Oncology (2019)

11050 Background: Efficacy of low-dose chemotherapy with methotrexate (MTX) and vinblastine (VBL) for desmoid-type fibromatosis (DF) has been reported and approved by many physicians. However, significant factors including biomarker could not be identified to better predict the efficacy of this chemotherapy. Since 2003, meloxicam, which is a selective COX-2 inhibitor, has been applied consecutively as a first line treatment. We applied the low-dose chemotherapy with MTX+VBL for refractory patients. The aim of this study was to reveal the clinical outcome of low-dose chemotherapy with MTX+VBL, and determine the useful factors to predict the efficacy including CTNNB1 mutation status. Methods: Since 2003, 167 cases were histologically diagnosed as DF. Among them, 36 cases were treated with MTX (30mg/M2) +VBL (6mg/M2) chemotherapy. Treatment interval was basically 2 weeks according to our previous study. Effectiveness was evaluated with MRI and/or CT every 3 months according to Response Evaluation Criteria in Solid Tumors (RECIST). Frozen or FFPE (Formalin-Fixed Paraffin-Embedded) specimens obtained at biopsy or previous surgery were subjected to the analyses for CTNNB1 mutation status by Sanger method. Clinical outcome and factors correlating with the efficacy were analyzed. Results: Among 36 cases with this chemotherapy, male was 13, mean age at the treatment was 36±18 years. Mean maximum diameter of tumor was 15±18 cm. Twenty-nine cases (81%) harbored CTNNB1 or APC mutation. Mean treatment duration and cycles of MTX+VBL were 20 months and 29 cycles, respectively. According to RECIST, PD in 2, PR 1n 15, and SD in 19. According to CTCAE, Grade 3 or more adverse events were observed in only one case. CTNNB1 mutation status, gender, age, size, and location did not affect the outcome of RECIST. Longer treatment duration and cycles of chemotherapy were significantly associated with the outcome (P = 0.002 and 0.004, respectively). In 15 cases of PR, recurrent tumors significantly took longer time to get efficacy (P = 0.027), and tumors arising in trunk and extremities tended to take longer time (P = 0.1). Conclusions: Low-dose MTX+VBL chemotherapy is effective and feasible treatment for refractory DF regardless of CTNNB1 mutation status. Occasionally it takes time to obtain objective response.
Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Raajit K. Rampal, Roni Tamari, Nan Zhang, Caroline Jane McNamara, Franck Rapaport, Rivka Litvin, Molly A. Maloy, Hugo Castro-Malaspina, Sergio Giralt, Rona Singer Weinberg, John Mascarenhas, Ruben A. Mesa, Damiano Rondelli, Amylou C. Dueck, Ross L. Levine, Vikas Gupta, Ronald Hoffman
Journal: Blood (2016)
Usefulness of NT-ProBNP as a biomarker of cardiotoxicity in breast cancer patients treated with trastuzumab
Authors: I. Blancas, C. Martín, F.J. Martín-Pérez, M. Legerén, M. Martos, S. Sequero, S. Carnenero, M.E. Pérez-García, C.J. Rodríguez-González, J.M. Jurado, M. Delgado, B. González-Astorga, I. González-Cebrián, J.M. Garrido, C. Prieto, V. Bayo-Martin, M.I. Fernández-Gutiérrez, G. Ayala-Carbonero, S. Reyes-Larzategui, F. Rodríguez-Serrano
Journal: Annals of Oncology (2019)
A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience
Authors: C. Pauli, T. Bochtler, L. Mileshkin, G. Baciarello, F. Losa, J. Ross, G. Pentheroudakis, G. Zarkavelis, S. Yalcin, M. Özgüroğlu, A. Beringer, S. Foser, J. Scarato, M. Mueller-Ohldach, H. Moch, A. Krämer
Journal: Annals of Oncology (2019)
Community-wide Screening for Tuberculosis in a High-Prevalence Setting
Authors: Guy B. Marks, Nhung V. Nguyen, Phuong T.B. Nguyen, Thu-Anh Nguyen, Hoa B. Nguyen, Khoa H. Tran, Son V. Nguyen, Khanh B. Luu, Duc T.T. Tran, Qui T.N. Vo, Oanh T.T. Le, Yen H. Nguyen, Vu Q. Do, Paul H. Mason, Van-Anh T. Nguyen, Jennifer Ho, Vitali Sintchenko, Linh N. Nguyen, Warwick J. Britton, Greg J. Fox
Journal: New England Journal of Medicine (2019)

The World Health Organization has set ambitious targets for the global elimination of tuberculosis. However, these targets will not be achieved at the current rate of progress.We performed a cluster-randomized, controlled trial in Ca Mau Province, Vietnam, to evaluate the effectiveness of active community-wide screening, as compared with standard passive case detection alone, for reducing the prevalence of tuberculosis. Persons 15 years of age or older who resided in 60 intervention clusters (subcommunes) were screened for pulmonary tuberculosis, regardless of symptoms, annually for 3 years, beginning in 2014, by means of rapid nucleic acid amplification testing of spontaneously expectorated sputum samples. Active screening was not performed in the 60 control clusters in the first 3 years. The primary outcome, measured in the fourth year, was the prevalence of microbiologically confirmed pulmonary tuberculosis among persons 15 years of age or older. The secondary outcome was the prevalence of tuberculosis infection, as assessed by an interferon gamma release assay in the fourth year, among children born in 2012.In the fourth-year prevalence survey, we tested 42,150 participants in the intervention group and 41,680 participants in the control group. A total of 53 participants in the intervention group (126 per 100,000 population) and 94 participants in the control group (226 per 100,000) had pulmonary tuberculosis, as confirmed by a positive nucleic acid amplification test for Mycobacterium tuberculosis (prevalence ratio, 0.56; 95% confidence interval [CI], 0.40 to 0.78; P<0.001). The prevalence of tuberculosis infection in children born in 2012 was 3.3% in the intervention group and 2.6% in the control group (prevalence ratio, 1.29; 95% CI, 0.70 to 2.36; P = 0.42).Three years of community-wide screening in persons 15 years of age or older who resided in Ca Mau Province, Vietnam, resulted in a lower prevalence of pulmonary tuberculosis in the fourth year than standard passive case detection alone. (Funded by the Australian National Health and Medical Research Council; ACT3 Australian New Zealand Clinical Trials Registry number, ACTRN12614000372684.).
BRAF-mutated colorectal metastases: What is the benefit of liver surgery? Results from a cohort of 91 patients
Authors: S. Javed, S. Benoist, CLa De Fouchardiere, S. Truant, D. Sefrioui, M.P. Galais, V. Hautefeuille, P. Artru, R. Guimbaud, R. Cohen, A. Lievre, J. Edeline, J.-B. Bachet, M. Gelli, A. Herrero, U. Marchese, M El Amrani, P. Devos, A. Turpin, A. Ploquin
Journal: Annals of Oncology (2019)
Updated survival analysis of the randomized phase III trial comparing S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (SALTO) by the Dutch colorectal cancer group
Authors: J.J. Kwakman, E. Van Werkhoven, L.H. Simkens, J.M. van Rooijen, A. van de Wouw, A.J. Ten Tije, G.-J. Creemers, M.P. Hendriks, M. Los, R. van Alphen, M.B. Polee, E.W. Muller, A. Van der Velden, T. Van Voorthuizen, M. Koopman, L. Mol, C.J.A. Punt
Journal: Annals of Oncology (2019)
Left Ventricular Ejection in Conscious Dogs:
Authors: MARK I. M. NOBLE, DIANA TRENCHARD, ABRAHAM GUZ
Journal: Circulation Research (1966)

Some factors affecting stroke volume were investigated in conscious dogs in which left ventricular outflow was measured with an electromagnetic flowmeter. Stimulation of the heart at constant heart rate, by intracoronary injections of calcium gluconate and isopropylnorepinephrine, or postectopic potentiation failed to produce any increase in stroke volume. By contrast, alterations of posture at constant heart rate with the presumed associated changes in end diastolic dimensions, produced large changes in stroke volume. This resulted from a change in late systolic flow.
Comparative molecular analyses between microsatellite stable BRAFV600E mutant colorectal cancers and BRAFV600E mutant melanomas
Authors: M.E. Salem, J. Xiu, A. Puccini, A. Grothey, R.M. Goldberg, J.J. Hwang, Z. Gatalica, R. Feldman, M. Saul, W.M. Korn, M.J. Hall, W. El-Deiry, A.F. Shields, J.L. Marshall, H.J. Lenz, A.M. VanderWalde
Journal: Annals of Oncology (2019)
Ancillary evaluation of systemic immune antitumour response (SIAR) and tumour growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase I study Mel-Ipi-Rx
Authors: C. Boutros, N. Chaput, E. Lanoy, A. Larive, C. Mateus, E. Routier, S. Roy, R. Sun, A. Lancia, Y. Tao, N. Ibrahim, R.M. Khoury-Abboud, C. Massard, R. Bahleda, D. Schwob, C. Caramella, L. Cassard, J.-C. Soria, C. Robert, E. Deutsch
Journal: Annals of Oncology (2019)
Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407
Authors: L. Paz-Ares, D. Vicente, A. Tafreshi, A. Robinson, H. Soto Parra, J. Mazières, B. Hermes, I. Cicin, B. Medgyasszay, B. Beatrix, J. Rodríguez Cid, I. Okamoto, S. Lee, R. Ramlau, V. Vladimirov, Y. Cheng, X. Deng, T. Bas, B. Piperdi, B. Halmos
Journal: Annals of Oncology (2019)
Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy
Authors: Chen Liu, Teli Liu, Jingjing Zhang, Richard P. Baum, Zhi Yang
Journal: Clinical Nuclear Medicine (2019)

Abstract Prostate cancer with neuroendocrine differentiation is associated with a poor prognosis, rapid disease progression, and treatment resistance, and constitutes a diagnostic and therapeutic dilemma. We present images of 177 Lu-DOTATATE scan and 68 Ga-DOTATATE PET/CT scan conducted on a 65-year-old man with prostate cancer with neuroendocrine differentiation, whose disease progressed despite conventional treatment and 177 Lu-PSMA radioligand therapy; however, an extraordinary radiographic tumor remission, biochemical response, and improvement of clinical symptoms were observed after the patient underwent 177 Lu-DOTATATE peptide receptor radionuclide therapy.
Capecitabine and docetaxel for advanced gastric cancer
Authors: P. C. Thuss-Patience, A. Kretzschmar, Y. Dogan, I. Blau, D. Pink, B. Lebedinzew, S. Micheel, B. Dörken, P. Reichardt
Journal: Journal of Clinical Oncology (2006)

4068 Background: Docetaxel is increasingly integrated into chemotherapy combination regimens against gastric cancer. Docetaxel and 5-FU were compared to ECF and appeared to be very active and well tolerated (Thuss-Patience et. al. JCO 2005). In the current study the dual combination capecitabine and docetaxel (CapDoc) is evaluated to develop a convenient out-patient regimen with minimal toxicity. Methods: Prospective multicenter phase II trial. Eligibility: Metastatic or locally advanced gastro-esophageal junction or gastric adenocarcinoma, ECOG PS 0–2, no prior palliative chemotherapy. Chemotherapy: Docetaxel 75 mg/m 2 d1, capecitabine 2000 mg/m 2 d1–14, q3w. For part I of the study (presented here) accrual is completed (40 pts). In part II we reduced the starting dose of docetaxel to 60 mg/m 2 and capecitabine to 1600 mg/m 2 to further improve tolerability (accrual ongoing, 8 pts included so far, presented at meeting). Results: 40 pts are included in this trial (part I). Age: 32–79 years (median 61), M/F 29/11, ECOG PS 0: 7 pts, 1: 27 pts, 2: 6 pts. Number of organs involved by metastases: 1: 9 pts, 2: 11 pts, 3: 16 pts, more than 3: 4 pts. Measurable disease (RECIST): 40 pts. 233 cycles of chemotherapy are administered so far. Toxicity: 40 pts are evaluable for toxicity (worst grade per patient; % of pts): Grade 1/2/3/4: Nausea: 53/10/3/- %, vomiting: 18/13/-/3 %, diarrhea: 23/20/13/- %, asthenia: 38/40/10/- %, stomatitis: 23/15/10/- %, alopecia: 25/53/-/- %, fever not neutropenic: 10/20/3/- %, neutropenic fever: -/-/10/3 %, nail changes: 33/28/-/- %, paresthesia: 18/18/5/- %, dizziness: 15/8/5/- %, hand-foot-syndrome: 25/18/18/- %, leuko-neutropenia: 8/13/25/28 %, thrombocytopenia: 18/-/-/- %, anemia: 40/15/5/- %, fluid retention: 13/5/-/-, pulmonary embolism or thrombosis: 3/5/3/5. Dose adjustments of docetaxel had to be made in 45% and of capecitabine in 55% of pts. Response: 26 of 37 pts with tumor related symptoms showed a subjective improvement of symptoms (70.3%). 38 pts are evaluable for objective response: CR 1 pt (2.6%), PR 20 pts (52.6%), NC 14 pts (36.8%), PD 3 pts (7.9%), (objective response rate: 55.3%). Median time to tumor progression 5.5 months, median survival 9.5 months. Conclusion: These data suggest that CapDoc is a well tolerated convenient out-patient combination with very promising efficacy. [Table: see text]
Prognostic impact of metastatic sites for pembrolizumab efficacy as first-line therapy in patients with PD-L1 tumour proportion score (TPS) ≥ 50% advanced non-small cell lung cancer: A retrospective multicenter study
Authors: H. Kawachi, M. Tamiya, A. Tamiya, S. Ishii, K. Hirano, H. Matsumoto, T. Yokoyama, T. Ishida, K. Ryota, D. Fujimoto, K. Hosoya, H. Suzuki, T. Hirashima, M. Kanazu, N. Sawa, J. Uchida, M. Morita, T. Makio, S. Hara, T. Kumagai
Journal: Annals of Oncology (2019)
Impact of timing and technique of gastrostomy placement on the outcome of patients (pts) with head and neck cancer (HNC)
Authors: M.J. Lostes Bardaji, N.M. Diaz, A. Hernando, C. Puiggrós, G. Vilacampa, J.D. Assaf, N. Saudi, J. Ros, A. Garcia, C. Bescós-Atin, J. Lorente, J. Giralt, C. Viaplana, M. Biosca, J. Tabernero, E. Felip, R. Dienstmann, I. Brana
Journal: Annals of Oncology (2019)
Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours
Authors: N. Girard, B. Hackanson, M. Wermke, F. Barlesi, H.T. Landsteiner, G. Jayadeva, J. Alt
Journal: Annals of Oncology (2019)
Health-related quality of life in patients with advanced soft tissue sarcomas treated with chemotherapy: The HOLISTIC study
Authors: E. Younger, O. Husson, I.M.E. Desar, R. Young, M.G. Leahy, A. Oosten, H. Gelderblom, J. de Haan, N. Steeghs, R.L. Jones, W.T. van der Graaf
Journal: Annals of Oncology (2019)
Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes
Authors: Bram Vrancken, Lize Cuypers, Ana Belen Pérez, Natalia Chueca, Joaquin Anton-Basantas, Alberto de la Iglesia, Javier Fuentes, Juan Antonio Pineda, Francisco Téllez, Enrique Bernal, Pilar Rincón, Miguel Angel Von Wichman, Ana Fuentes, Francisco Vera, Antonio Rivero-Juárez, Miguel Jiménez, Anne-Mieke Vandamme, Federico García
Journal: Journal of Hepatology (2019)
Validation of the geriatric vulnerability score (GVS) in older ovarian cancer (oOC) patients: An analysis from the GCIG-ENGOT-GINECO EWOC-1 study
Authors: F. Tinquaut, G. Freyer, F. Pommeret, L. Gladieff, D. Lorusso, M A Mouret Reynier, V. D’Hondt, D. Mollon-Grange, A. Floquet, S Abadie Lacourtoisie, P.E. Brachet, L. Stefani, F. Rousseau, J.-S. Frenel, F.l. De Piano, J. Herrstedt, T. Warkus, O. Tredan, E. Pujade-Lauraine, C. Falandry
Journal: Annals of Oncology (2019)
Phase III KEYNOTE-048 study of first-line (1L) pembrolizumab (P) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Asia vs non-Asia subgroup (subgrp) analysis
Authors: M. Tahara, R.-L. Hong, W.Z. Wan Ishak, C.-J. Yen, V. Sriuranpong, S. Takahashi, V. Srimuninnimit, S.-P. Yeh, N. Oridate, M.-H. Yang, K. Tanaka, N. Nohata, Y. Koh, A. Roy, B. Gumuscu, R.F. Swaby, N. Ngamphaiboon
Journal: Annals of Oncology (2019)
Carcinoid heart disease (CHD): the CRUSOE-NETs, a prospective cohort study from the French group of endocrine tumours (GTE)
Authors: K. Dekeister Geoffroy, L. Francois, T. Walter, O. Hentic Dhome, A. Cachier, G. Cadiot, P. Nazeyrollas, P. Afchain, S. Ederhy, C. Lepage, J.-C. Eicher, R. Coriat, L. Cabanes, E. Baudin, S. Dominguez, F. Delelis, J. Forestier, C. Lombard Bohas
Journal: Annals of Oncology (2019)
Spatial-temporal change in quantitative total bone imaging (QTBI) and circulating tumour cells (CTCs) in metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA)
Authors: G. Liu, C.E. Kyriakopoulos, J.M. Lang, J.M. Sperger, A. Singh, E.I. Heath, S. Perlman, T. Mayer, K. Modelska, A. Porcari, W. Duggan, R. Jeraj
Journal: Annals of Oncology (2019)
KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
Authors: J. Cortés, O. Lipatov, S.-A. Im, A. Gonçalves, K.S. Lee, P. Schmid, K. Tamura, L. Testa, I. Witzel, S. Ohtani, S. Zambelli, N. Harbeck, F. André, R. Dent, X. Zhou, V. Karantza, J.A. Mejia, E.P. Winer
Journal: Annals of Oncology (2019)
A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck
Authors: P. Bossi, M.C. Merlano, M.G. Ghi, G. Rinaldi, F. Caponigro, F. Morelli, M. Airoldi, A. Farnesi, A. Cassano, D. Ferrari, A. Mirabile, A. Tosoni, D. Galizia, G. Moretti, A.P. Sponghini, G. Calareso, A. Vingiani, F. Perrone, A. Falletta, L.F. Licitra
Journal: Annals of Oncology (2019)
Real-world treatment sequencing patterns in secondary breast cancer (SBC): Pathway visualisation using national datasets
Authors: A.W.B. Horne, M. McMenemy, E. Holly, N. Rigglesford, P. Linksted, L. Murdoch, O. Oikonomidou, C. Michie, L. Hayward, C. Lilley, P. Hall
Journal: Annals of Oncology (2019)
First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumours
Authors: M. Yunokawa, S. Takahashi, D. Aoki, K. Yonemori, H. Hara, K. Hasegawa, K. Takehara, K. Harano, H. Nomura, E. Noguchi, K. Horie, A. Ogasawara, S. Okame, T. Doi
Journal: Annals of Oncology (2019)
Making sport and sports medicine history—Lillehammer 1994, 2019 and 2021
Authors: Hilde Moseby Berge
Journal: British Journal of Sports Medicine (2019)

Welcome to this scintillating Norwegian issue of the BJSM. The Scandinavian knee ligament registries ( See page 1259 ) were established 15 years ago, and they now inform us with data from >70 000 patients. Did you know that you can lower the risk of revision anterior cruciate ligament (ACL) reconstruction for hamstring versus patella tendon autograft by 14% for every 0.5 mm increase in hamstring graft diameter?1 

In a cohort of professional male Norwegian football players followed up after 8 years ( See page 1279 ), we found that 6 of the 595 players with negative preparticipation cardiac screening suffered a severe cardiovascular event; three of these six events were sudden cardiac arrests (SCA). Rather than introducing more preparticipation cardiac screening in Norway, we will focus on recognising athletes with early symptoms of cardiac disease. We will examine them thoroughly, and be prepared to treat SCA by having staff well trained and AEDs widely available. It is critical to recognise SCA early as proven by another Norwegian study ( See page 1293 ) where authors analysed 35 sports-related SCAs that were captured on video. Agonal respiration, prone landing, …
Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8
Authors: Hao-Chen Wang, Yung-Lun Lin, Ching-Cheng Hsu, Ying-Jui Chao, Ya-Chin Hou, Tai-Jan Chiu, Po-Hsien Huang, Ming-Jer Tang, Li-Tzong Chen, Yan-Shen Shan
Journal: Theranostics (2019)

Background:The dense fibrotic stroma enveloping pancreatic tumors is a major cause of drug resistance.Pancreatic stellate cells (PSCs) in the stroma can be activated to induce intra-tumor fibrosis and worsen patient survival; however, the molecular basics for the regulation of PSC activation remains unclear.Methods: The in vitro coculture system was used to study cancer cell-PSC interactions.Atomic force microscopy was used to measure the stiffness of tumor tissues and coculture gels.Cytokine arrays, qPCR, and Western blotting were performed to identify the potential factors involved in PSC activation and to elucidate underlying pathways.Results: PSC activation characterized by α-SMA expression was associated with increased pancreatic tumor stiffness and poor prognosis.Coculture with cancer cells induced PSC activation, which increased organotypic coculture gel stiffness and cancer cell invasion.Cancer cells-derived PAI-1 identified from coculture medium could activate PSCs, consistent with pancreatic cancer tissue microarray analysis showing a strong positive correlation between PAI-1 and α-SMA expression.Suppression by knocking down PAI-1 in cancer cells demonstrated the requirement of PAI-1 for coculture-induced PSC activation and gel stiffness.PAI-1 could be upregulated by KRAS in pancreatic cancer cells through ERK.In PSCs, inhibition of LRP-1, ERK, and c-JUN neutralized the effect of PAI-1, suggesting the contribution of LRP-1/ERK/c-JUN signaling.Furthermore, activated PSCs might exacerbate malignant behavior of cancer cells via IL-8 because suppression of IL-8 signaling reduced pancreatic tumor growth and fibrosis in vivo.Conclusions: KRAS-mutant pancreatic cancer cells can activate PSCs through PAI-1/LRP-1 signaling to promote fibrosis and cancer progression.
AB0798 Clinical associations of vascular endothelial growth factor and its receptor 2 type in systemic sclerosis
Authors: R. Alekperov, E. Alexandrova, A. Novikov, L. Ananyeva
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Systemic sclerosis (SSc) is characterised by impaired angiogenesis and peripheral microvasculopathy. A major role in the regulation of angiogenesis attributed to vascular endothelial growth factor, which performs its functions through interaction with its receptor 2 type (VEGFR2). <h3>Objectives</h3> The aim of our study was to assess the levels of VEGF in serum and its associations with clinical manifestations in patients with SSc. <h3>Methods</h3> We studied 46 patients with SSc who underwent clinical examination, pulmonary function tests and echocardiography. Serum VEGF-A and VEGFR2 levels were determined by ELISA in 46 SSc patients and 20 healthy controls <h3>Results</h3> Mean VEGF levels were increased in SSc patients compared to controls (212,35±253,93 and 97,74±71,46 pg/ml, respectively; p=0,032). Patients with limited cutaneous SSc (n=23) had higher levels of serum VEGF than those with diffuse cutaneous SSc (n=23) (267,11±268,74 vs 120,40±141,09 pg/ml; p=0,012). Patients with fingertip ulcers (n=19) were found to have higher levels of VEGF than pts without fingertip ulcers.(n=27) (214,25±265,93 vs 162,88±188,97) but this difference wasn't significant. Serum VEGF levels were higher in SSc patients with sPAP &gt;30 mmHg than in those with sPAP ≤30 mmHg (286,51±287,42 vs 92,88±108,06 pg/ml; p=0,0042) and correlated with sPAP values (R=0,40; p=0,007). Mean VEGF levels in patients with DLCO &lt;50% (n=14) were significantly higher than those with DLCO ≥50% (n=30): 364,20±381,95 vs 128,55±142,70 pg/ml, respectively (p=0,034). There weren't significant differences in VEGF levels between patients with FVC &lt;80% (n=11) and those with FVC ≥80% (219,15±252,57 vs 154,26±208,91 pg/ml, respectively). Mean VEGFR2 levels were also increased in SSc pts compared to controls (5784,6±4773,8 and 1552,6±272,8 pg/ml, respectively; p&lt;0,0001). There weren't any differences between pts with diffuse or limited SSc. In pts with digital ulcers, or normal levels of sPAP, or DLco ≥50% mean VEGFR2 levels didn't differ from those without digital ulcers, or sPAP &gt;30 mm Hg, or DLco &lt;50%, respectively. Serum VEGF levels directly correlated with sPAP (R=0,40; p=0,007). <h3>Conclusions</h3> Our findings show significantly higher circulating levels of VEGF and VEGFR2 in SSc patients. Associations of VEGF with some clinical signs indicate its role in pathology of SSc. <h3>Disclosure of Interest</h3> None declared